Indian generic drugmaker settles lawsuit with Leo Pharma

Glenmark, an Indian developer of generic medicines, has agreed to a confidential settlement with Leo Pharma concerning a generic version of the Danish firm’s foam treatment for plaque psoriasis.

Photo: Leo Pharma/PR

Leo Pharma’s lawsuit against Indian generic drugmaker Glenmark has concluded in a settlement, Leo Pharma informs MedWatch by email.

”The lawsuit resolved in a confidential settlement in April. Leo Pharma is pleased that the patent infringement case against Glenmark has been settled,” writes Leo Pharma’s patent department in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs